141 related articles for article (PubMed ID: 38059638)
1. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
Kozuch JM; Burt C; Afshar K; Aslam S; Yung G; Mariski M; Golts E; Feist A
Transpl Infect Dis; 2024 Feb; 26(1):e14209. PubMed ID: 38059638
[TBL] [Abstract][Full Text] [Related]
2. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
Peksa GD; Schultz K; Fung HC
J Oncol Pharm Pract; 2015 Dec; 21(6):409-15. PubMed ID: 24938293
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations.
Gu TM; Lewis JS; Le H; Bubalo JS
J Oncol Pharm Pract; 2022 Sep; 28(6):1357-1362. PubMed ID: 34192963
[TBL] [Abstract][Full Text] [Related]
4. Management of drug and food interactions with azole antifungal agents in transplant recipients.
Dodds-Ashley E
Pharmacotherapy; 2010 Aug; 30(8):842-54. PubMed ID: 20653361
[TBL] [Abstract][Full Text] [Related]
5. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.
Sansone-Parsons A; Krishna G; Martinho M; Kantesaria B; Gelone S; Mant TG
Pharmacotherapy; 2007 Jun; 27(6):825-34. PubMed ID: 17542765
[TBL] [Abstract][Full Text] [Related]
7. Effect of letermovir initiation on tacrolimus concentrations among lung transplant recipients receiving concomitant azole antifungal prophylaxis.
Goodlet KJ; Garcia R
Transpl Infect Dis; 2024 Apr; 26(2):e14267. PubMed ID: 38488776
[TBL] [Abstract][Full Text] [Related]
8. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice.
Lempers VJ; Martial LC; Schreuder MF; Blijlevens NM; Burger DM; Aarnoutse RE; Brüggemann RJ
Curr Opin Pharmacol; 2015 Oct; 24():38-44. PubMed ID: 26218924
[TBL] [Abstract][Full Text] [Related]
9. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
10. Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients.
Silva JT; Husain S; Aguado JM
Transpl Int; 2023; 36():11845. PubMed ID: 38161768
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients.
Vanhove T; Bouwsma H; Hilbrands L; Swen JJ; Spriet I; Annaert P; Vanaudenaerde B; Verleden G; Vos R; Kuypers DRJ
Am J Transplant; 2017 Sep; 17(9):2372-2380. PubMed ID: 28224698
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.
Groll AH; Desai A; Han D; Howieson C; Kato K; Akhtar S; Kowalski D; Lademacher C; Lewis W; Pearlman H; Mandarino D; Yamazaki T; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):76-85. PubMed ID: 27273343
[TBL] [Abstract][Full Text] [Related]
13. Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients.
Rivosecchi RM; Clancy CJ; Shields RK; Ensor CR; Shullo MA; Falcione BA; Venkataramanan R; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674051
[TBL] [Abstract][Full Text] [Related]
14. Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies.
Gatti M; Campoli C; Belotti T; Cojutti PG; Masetti R; Pession A; Viale P; Pea F
Ther Drug Monit; 2022 Oct; 44(5):641-650. PubMed ID: 35344524
[TBL] [Abstract][Full Text] [Related]
15. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
[TBL] [Abstract][Full Text] [Related]
16. Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review.
Fu C; Chen J; Xu Y; Wu D
Clin Invest Med; 2018 Mar; 41(1):E5-E15. PubMed ID: 29603686
[TBL] [Abstract][Full Text] [Related]
17. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
18. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation.
Mimura A; Yamaori S; Ikemura N; Katsuyama Y; Matsuzawa N; Ohmori S
J Clin Pharm Ther; 2019 Aug; 44(4):565-571. PubMed ID: 30950099
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
